On February 13, 2024, the Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma
Starpharma's Dep Irinotecan combination cancer drug has shown to be superior to Onivyde
Ipsen purchased Onivyde from Cambridge, Massachusetts-based Merrimack Pharmaceuticals in 2017 with an upfront payment of $575 million, plus US$450 million in potential milestones based on label expansions
https://www.onivyde.com/en-us/for-patients
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
-0.005(4.00%) |
Mkt cap ! $50.18M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 11.5¢ | $3.755K | 31.66K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 63402 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 106947 | 2 |
View Market Depth
| Last trade - 15.41pm 12/09/2025 (20 minute delay) ? |
| SPL (ASX) Chart |